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Purpose: To compare the clinical manifestations between patients with ocular myasthenia gravis and those with 
generalized myasthenia gravis (MG). 
Methods: The medical records of 71 patients diagnosed with MG between January 1995 and December 2007 were 
reviewed. Demographics, sensitivities of diagnostic methods, the presence of systemic autoimmune diseases, 
ophthalmic complications caused by MG, and treatments were evaluated and compared.
Results: Fourteen patients (20%) were diagnosed with ocular MG and 57 patients (80%) with generalized MG. 
Sensitivities of anti-acetylcholine receptor antibody and repetitive nerve stimulation tests were significantly higher 
in the generalized MG group (84%, 89%) compared to those in the ocular MG group (50%, 54%) (p = 0.011, p = 
0.008). The sensitivity of the neostigmine test was the highest in both groups (98% of generalized MG, 79% of oc-
ular MG), and the difference between the two groups was borderline significant (p = 0.058). The most common 
symptoms were ptosis and diplopia, and both groups presented with pain, blurred vision, and tearing. Systemic 
autoimmune disease was more prominent in the generalized MG group (21%) than in the ocular MG group (14%), 
and steroid therapy was used more frequently in the generalized MG group (82%) than in the ocular MG group 
(57%). Ophthalmic complications associated with long-term steroid treatment were more profound in the general-
ized MG (30%) compared to those of the ocular MG (21%).
Conclusions: The generalized MG group was associated with higher sensitivities to diagnostic tests, more systemic 
steroid use, higher ophthalmic complications caused by systemic autoimmune disease, and long-term steroid 
treatment compared to those of the ocular MG group.
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Myasthenia gravis (MG) is an autoimmune disease charac-
terized by muscular fatigue due to defective neuromuscular 
transmission, with the levator palpebralis and extraocular 
muscles preferentially affected [1]. More than three-quarters 
of MG patients present with visual complaints such as droo-
py eyelids or double vision, and about half of patients who 
present with ocular manifestations develop generalized 
weakness within six months. Approximately 80% of MG pa-
tients will generalize within two years and approximately 
90% within three years [2-5]. The first and sometimes only 
manifestations of MG are ocular including fluctuating dip-
lopia and/or ptosis worsened by exertion. Several retro-
spective studies have suggested that early treatment with oral 
prednisolone can delay the onset and possibly decrease the 
frequency of progression from ocular MG to generalized 
MG. High-dose oral prednisolone over a period of two to 
three months is generally required to induce remission 
[6-12]. 
MG patients are more likely to develop other immune-re-
lated disorders including type I diabetes mellitus, Graves dis-
ease, Hashimoto disease, systemic lupus erythematosus, 
rheumatoid arthritis, Sjogren syndrome or multiple sclerosis 
[11,12]. These autoimmune diseases may be associated with 
ophthalmic symptoms including blurry vision, tearing, pain, 
photophobia, foreign body sensation, and ophthalmic signs 
including reduced visual acuity, decreased tear film, in-
flammatory soft tissue, exophthalmos, and lid retraction that Korean J Ophthalmol Vol.25, No.1, 2011
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Table 1. Demographic characteristics in myasthenia gravis (MG) patients
　
          MG patients
Total MG Ocular MG Generalized MG p-value 
Gender (male) 28 (38) 7 (50) 21 (37) 0.367
*
Age (yr) 48.5 ± 16.1 50.4 ± 20.6 48.1 ± 14.9 0.430
†
Age at onset of symptom (yr) 41.2 ± 16.9 41.4 ± 25.1 41.1 ± 14.6 0.490
†
Thymectomy     40 (56)     3 (21)     37 (65) 0.003
*
Abnormal AchR antibody 55/71 (78) 7/14 (50) 48/57 (84) 0.011
§
Abnormal neostigmine test
‡ 63/67 (94) 11/14 (79) 52/53 (98) 0.058
§
Abnormal RNST
‡ 56/68 (82) 7/13 (54) 49/55 (89) 0.008
§
Patients 71 14 57
Values are presented as mean ± SD or number (%).
AchR = acetylcholine receptor; RNST = repetitive nerve stimulation test.
*According to Pearson’s chi-square test; 
†According to Wilcoxon rank sum test; 
‡Total number of patients for which the test/procedure was 
performed; 
§According to Fisher’s exact test.
Thymoma (histologically confirmed)
Ocular myasthenia gravis
Generalized myasthenia gravis
n=2 8 n=4 3
Fig. 1. Age of onset according to gender. 
can occur along with the typical MG symptoms of ptosis and 
ocular motility defects. 
To date, previous studies of MG have not focused on oph-
thalmic manifestations other than ptosis, diplopia and those 
caused by the long-term treatment of MG. There are no 
known studies comparing the ophthalmic features and com-
plications between patients with ocular MG and those of gen-
eralized MG. Therefore, we compared the demographics, 
clinical ophthalmic features of MG, sensitivities of MG diag-
nostic methods, systemic treatment of MG, the presence of 
systemic autoimmune diseases, and the ophthalmic compli-
cations caused by MG itself, other associated autoimmune 
diseases and long-term steroid treatment between ocular and 
generalized MG patients. 
Materials and Methods
Patients diagnosed with MG between January 1995 and 
December 2007 with a minimum follow-up period of one 
year were selected from the database of the Department of 
Neurology and Ophthalmology, Yonsei University College 
of Medicine. Data from the early phase of the disease and di-
agnosis were collected from medical charts with an emphasis 
on demographic data, ophthalmic symptoms and signs, other 
associated autoimmune diseases, and the results of diag-
nostic tests. The diagnosis of MG was determined primarily 
through clinical evaluation and confirmatory diagnostic tests 
including one or more of the following: anti-acetylcholine re-
ceptor antibody test, repetitive nerve stimulation test, neo-
stigmine test and significant response to a longer acting ace-
tylcholinesterase antagonist (pyridostigmine). Sensitivities 
of the anti-acetylcholine antibody test, repetitive nerve stim-
ulation test, and neostigmine test were evaluated and com-
pared between ocular MG and generalized MG groups.
Patients were classified according to the modified 
Osserman score: grade I, focal disease (ocular MG, restricted 
to the ocular muscle); grade II, generalized disease that is ei-
ther mild (IIa) or moderate (IIb); grade III, acute severe gen-
eralized disease with respiratory failure; and grade IV, severe 
generalized disease with respiratory failure (progression 
within two years) [13]. Patients were classified into two 
groups of ocular (grade I) and generalized MG (grade II-IV). 
All patients underwent contrast-enhanced computed tomog-
raphy of the chest to screen for thymoma. Patients with radio-
logically-diagnosed thymoma were operated on if their gen-
eral condition allowed for surgical intervention. The oph-
thalmic symptoms and signs associated with MG including 
ptosis, diplopia, and caused by long-term steroid treatment 
were compared between the ocular MG and generalized MG 
groups. Statistical analysis was performed using SPSS ver. 
12.0 (SPSS Inc., Chicago, IL, USA). Categorical variables 
were analyzed using the Pearson’s chi-square and the 
Fisher’s exact tests, while continuous variables were ana-
lyzed with the Wilcoxon rank sum test. A p-value of less than 
0.05 was considered statistically significant.
Results
A total of 71 patients with a median of 39 months (range, 
12 to 105 months) follow-up were included in this study. The 
mean age was 48.5 years (standard deviation [SD], 16.1 
years; range, 7 to 80 years), and the female to male ratio was HS Roh, et al. Ocular and Generalized Myasthenia Gravis
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Table 2. Ophthalmic symptoms and signs in myasthenia gravis (MG) patients
MG patients
Total MG Ocular MG Generalized MG p-value
Symptom
Pain 29 (41)   6 (43) 23 (40) 0.864
†
Blurred vision 17 (24)   4 (28) 13 (23) 0.730
‡
Tearing 23 (32)   5 (36) 18 (32) 0.759
‡
Ptosis  62 (87)  13 (93) 49 (86) 0.677
‡
Diplopia 66 (93)  13 (93) 53 (93) 1.000
‡
Sign
Dry eye
* 19 (27)  3 (21) 16 (28) 0.745
‡
Exposure keratitis  1 (1) 0 1 (2) NA
Lid retraction 2 (3) 0 2 (4) NA
Eyelid swelling or erythema 3 (4) 1 (7) 2 (4) 0.488
‡
Cataract 12 (17) 1 (7) 11 (19) 0.437
‡
Open angle glaucoma  5 (7) 1 (7) 4 (7) 1.000
‡
Central serous chorioretinopathy  3 (4) 1 (7) 2 (4) 0.488
‡
Total 71 14 57
Values are presented as number (%).
NA = not available or insufficient data available for analysis.
*Dry eye with a Schirmer test result of less than 10 mm or a BUT less than 10 seconds; 
†According to Pearson’s chi-square test; 
‡According 
to Fisher’s exact test. 
1.56:1. The mean age at disease onset was 41.8 years (SD, 
16.9 years; range, 3 to 71 years), and initial symptoms devel-
oped before the age of 50 in 65% (46/71) of MG patients. 
Using the modified Osserman score, patients were classi-
fied as I (20%), IIa (16%), IIb (39%), III (21%), and IV (4%). 
Fourteen patients presented with ocular MG and 57 patients 
with generalized MG. In patients with generalized MG, the 
mean time interval from the onset of ocular MG to general-
ization was 3.5 years. Table 1 presents the comparative dem-
ographic and clinical characteristics. Age, gender, and age of 
disease onset were not significantly different between the oc-
ular MG and generalized MG groups. Thymoma was radio-
logically diagnosed and surgically resected in 40 patients 
(56%, 27 women and 13 men), with 22 cases of histologi-
cally confirmed thymoma postoperatively (ocular MG, 3 pa-
tients; generalized MG, 19 patients). Thymectomy was per-
formed significantly more in the generalized MG group 
(65%) than in the ocular MG group (21%) (p = 0.003, Fisher’s 
exact test). The remaining 18 patients with generalized MG 
had hyperplastic thymus (n = 14) or normal histology (n = 4).
Fig. 1 presents the distribution for age of disease onset ac-
cording to gender. The criteria in Fig. 1 are based on the re-
port by Beekman et al. [14]. Mean age of disease onset was 
40.1 years (SD, 13.6 years; range, 3 to 67 years) in male MG 
patients and 42.8 years (SD, 13.9 years; range, 3 to 69 years) 
in female MG patients. The ages of disease onset were not 
significantly different between female and male MG groups 
(p = 0.693, Wilcoxon rank sum test). 
  The anti-acetylcholine receptor antibody test was per-
formed in 71 patients, repetitive nerve stimulation test in 68 
patients and neostigmine test in 67 patients (Table 1). The 
sensitivities of the anti-acetylcholine receptor antibody and 
repetitive nerve stimulation tests were significantly higher in 
the generalized MG group (84%, 89%, respectively) com-
pared to those in the ocular MG group (50%, 54%, re-
spectively) (p = 0.011, p = 0.008, respectively). The sensitiv-
ities of the neostigmine tests were higher in both groups 
(98% in the generalized MG group and 79% in the ocular 
MG group) compared to those of the other tests, and the dif-
ference between the two groups was borderline significant (p 
= 0.058). 
The ophthalmic symptoms and signs in the ocular MG 
group and the generalized MG group are provided in detail in 
Table 2. In the total 71 patients, 87% presented with fluctuat-
ing ptosis and 93% presented with diplopia. Although 100% 
of the ocular MG group presented with ptosis or diplopia, 7% 
of the generalized MG group had no ptosis or diplopia. 
Interestingly, other ophthalmic symptoms including ocular 
pain, blurred vision, and tearing were observed in both MG 
groups (24% to 41%); however, the incidences were not sig-
nificantly different between the ocular MG group and the 
generalized MG group. Ophthalmic signs such as dry eye, 
exposure keratitis, lid retraction, lid swelling, lid erythema, 
cataract, glaucoma, and central serous chorioretinopathy 
were present and were associated with muscle weakness 
caused by MG, systemic autoimmune diseases, and/or 
long-term steroid treatment. One patient from the general-
ized MG group presented with exposure keratitis due to poor 
eyelid closure caused by facial weakness. Nineteen patients 
(21% of ocular MG and 28% of generalized MG) were diag-
nosed with dry eye syndrome according to the Schirmer test 
(<10 mm) and tear break up time (less than 10 seconds) with 
dry eye symptoms such as pain or tearing. One patient with 
dry eye was diagnosed with Sjogren’s syndrome with docu-Korean J Ophthalmol Vol.25, No.1, 2011
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Table 3. Associated autoimmune diseases
　Symptom
MG patients
Ocular MG Generalized MG
Rheumatoid arthritis 0 1 (2)
Systemic lupus erythematosus 0 1 (2)
Hyperthyroidism 1 (7) 4 (7)
Hypothyroidism  1 (7) 3 (5)
Multiple sclerosis 0 1 (2)
Behcet‘s disease 0 1 (2)
Sjogren’s syndrome 0 1 (2)
Total 2 (14) 12 (21)
Values are presented as number (%).
MG = myasthenia gravis.
Table 4. Treatment modalities of myasthenia gravis (MG)
　
MG patients
Total MG Ocular MG Generalized MG p-value
Acetylcholinesterase inhibitors  16 (20) 6 (44) 10 (20) 0.070
*
Prednisone 55 (77) 8 (57) 47 (82) 0.070
*
Steroid pulse therapy 23 (31) 3 (21) 20 (35) 0.525
*
Combined with non-steroidal immunosuppressant 24 (34) 2 (14) 22 (39) 0.118
*
Plasmapheresis 2 (3) - 2 (4) NA
No treatment 0 (0) - - -
Patients 71 14 57
Values are presented as number (%).
NA = not available.
*According to Fisher’s exact test.
mented elevated levels of anti-nuclear antibodies including 
SSA/Ro and SSB/La. Patients with lid retraction (n = 2), lid 
swelling or erythema (n = 3) were diagnosed with thyroid- 
associated ophthalmopathy and presented with generalized 
MG, except for one patient who presented with ocular MG. 
Five patients (ocular MG, 1;  generalized MG, 4) were diag-
nosed with open angle glaucoma after long-term steroid 
treatment for MG and presented with visual field defects and 
required anti-glaucoma eye drops or filtering surgery to con-
trol intraocular pressure. Twelve patients (ocular MG, 1; gen-
eralized MG, 11) presented with cataract after the diagnosis 
of MG, nine of whom had posterior subcapsular cataract and 
three of whom had mixed type of cataract. During the fol-
low-up period, three of those 12 patients required cataract 
surgery. Three patients with a history of steroid treatment for 
a mean of 6.1 years developed central serous chorioretinop-
athy; one patient developed central serous chorioretinopathy 
immediately after intravenous steroid pulse therapy.
As presented in Table 3, associated autoimmune diseases 
were present in 14 patients (20%, seven women and seven 
men), and although the generalized MG group had a higher 
incidence (21%, 12/57) compared to that of the ocular MG 
group (14%, 2/14), the difference was not statistically sig-
nificant (p = 0.721). Five patients had ocular involvement of 
Graves hyperthyroidism with abnormal thyroid stimulating 
antibody and thyroid hormone levels; one patient required 
three-wall decompression surgery for compressive optic 
neuropathy. Four patients (6%) had hypothyroidism with-
out ophthalmopathy, diagnosed as Hashimoto’s thyroiditis. 
The other associated diseases were rheumatoid arthritis (n = 1), 
systemic lupus erythematosus (n = 1), multiple sclerosis (n = 1), 
Sjogren’s syndrome (n = 1), and Behcet’s disease (n = 1). 
Among the 12 patients with autoimmune diseases, all except 
two patients with Graves’ hyperthyroidism and Hashimoto’s 
thyroiditis presented with generalized MG.
Sixteen patients were treated with only an anticholinesterase 
drug such as pyridostigmine or dosmin (Table 4). The per-
centage of patients who were only treated with acetylcholi-
nesterase inhibitor was much higher in the ocular MG group 
(44%) than in the generalized MG group (20%), although 
the difference was not statistically significant (p =0 . 0 7 ) .  
Prednisolone was administered orally to 55 patients (77%) 
who were not controlled with pyridostigmine; this low-dose 
prednisone was maintained until complete remission. 
Twenty-three of the 55 patients received high dose intravenous 
steroid pulse therapy for myasthenic crises. Prednisolone and 
intravenous high dose steroid pulse therapy were administered 
to the generalized MG patients (82% and 35%) more fre-
quently than it was to the ocular MG group (57% and 21%, 
respectively), although the differences were not statistically 
significant (p = 0.07, p = 0.525, respectively). Two generalized 
MG patients in myasthenic crisis required plasmapheresis. 
Two ocular MG patients (14%) and 22 generalized MG pa-
tients (39%) were treated with prednisolone combined with 
another non-steroidal immunosuppressant such as azathio-
prine, cyclosporine and cyclophosphamide.  
Discussion
This is the first study comparing the ophthalmic manifes-
tations and complications associated with MG, systemic au-
toimmune disease and long-term steroid treatment. As MG is 
a rare disease, it is often difficult to analyze a large patient 
population. We evaluated 71 patients that were followed for 
at least one year and analyzed and compared the demo-HS Roh, et al. Ocular and Generalized Myasthenia Gravis
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graphics, clinical manifestations, diagnoses and treatment 
modalities between the ocular and generalized MG groups. 
The most common symptoms seen in patients with MG are 
ptosis and diplopia. As expected, the majority of the ocular 
MG and generalized MG groups presented with ptosis (87%) 
or diplopia (93%). Eleven percent (8/71) of the generalized 
MG patients had only ptosis, 17% (12/71) experienced only 
diplopia, while the majority (76%, 54/71) suffered from both 
ptosis and diplopia. In the ocular MG group, less than 10% 
had ptosis only (1/14) or diplopia only (1/14), while 79% 
(12/14) had both ptosis and diplopia. A significant number of 
patients reported various ophthalmic symptoms such as tear-
ing (32%), pain (41%), and blurred vision (24%), all of 
which may be related to the muscular weakness caused by 
MG. Interestingly, these symptoms were observed equally in 
the ocular and the generalized MG groups. Since patients 
with MG have difficulty blinking, dryness, irritation and 
weakness may occur. Weakness of the orbicularis muscles 
that control eye closure may result in excessive tearing due to 
incomplete blinking. Artificial tears and forced blinking may 
help to reduce these ocular-irritating symptoms. 
The neostigmine test has a relatively high sensitivity, 94% 
to 100% for generalized MG and 69% to 91% for ocular MG 
[14]. Consistent with previous studies, the results of the neo-
stigmine test presented sensitivity rates of 98% for general-
ized MG and 79% for ocular MG in this study. In addition, 
78% of MG-diagnosed patients were positive for anti-ace-
tylcholine receptor antibody (50% in ocular MG, 84% in 
generalized MG), in agree with the results of previous stud-
ies, which have reported sensitivities ranging from 73% to 
93% in MG patients [14-16]. When the repetitive nerve stim-
ulation test was performed in 68 patients, the positive rate 
was low in ocular MG patients (54%) and relatively high in 
generalized MG patients (89%). The repetitive nerve stim-
ulation test has been shown to have a high sensitivity (74% to 
84%) for generalized MG but a low sensitivity (22% to 36%) 
for ocular MG [17]. In conclusion, the basic diagnostic meth-
ods for MG had lower sensitivities in the ocular MG group 
compared to those in the generalized MG group, in agree-
ment with previous reports. The ice test, in which sensitiv-
ities are reported to be 80% to 94% [18,19], may be a good al-
ternative diagnostic method; however, we could not compare 
the results of the ice test between the ocular and generalized 
MG groups as this test was performed in only a small number 
of patients with ocular MG (data not presented).
A bimodal pattern of age of onset has been recognized in 
both genders of MG patients, with an early-onset peak be-
tween ages 20 to 30 years and a late-onset peak between ages 
70 to 75 years [20]. Incidence rates in both genders increase 
with age, peaking between 60 to 80 years, with an apparent 
male predominance in the older age group [21]. In this study, 
the mean age of disease onset of was 40.1 years in male MG 
patients and 42.8 years in female MG patients, and the peak 
incidence was between ages 30 to 39 years in males and be-
tween 50 to 59 years in females, as presented in Fig. 1.
Twenty percent (n = 14) of the patients had autoimmune 
diseases associated with MG, with thyroid diseases being the 
most frequent (13.0%). Epidemiological studies have shown 
that thyrotoxic myopathy resulting from autoimmune thyroid 
disease occurs in approximately 5% to 10% of patients with 
MG [22], and similar findings were reported in a study from 
Denmark [23]. Five patients presented with symptoms of 
thyroid-associated ophthalmopathy (7.0%, one ocular MG, 
four generalized MG). Patients also presented with asso-
ciated autoimmune diseases such as rheumatoid arthritis, 
Sjogren’s syndrome, multiple sclerosis, and Behcet’s disease. 
Although statistical comparison of incidences of autoimmune 
diseases between the ocular and generalized MG groups was 
not possible due to the small sample size, the incidence of to-
tal autoimmune disease was higher in patients in the general-
ized MG group (21%, 12/57) than it was in the ocular MG 
group (14%, 2/14). The prevalence of concurrent auto-
immune diseases in a previous study was also higher in the 
generalized MG group (25%, 3/12) compared to that in the 
ocular MG group (19%, 5/27) [23].
Both ocular and generalized MG patients experience re-
missions and exacerbations on a regular basis. Treatment 
medications include anticholinesterase inhibitors, steroids 
and other immunosuppressants either alone or in combination. 
Thymectomy is often recommended for generalized MG pa-
tients; however, this procedure is rarely performed in purely 
ocular MG patients [24]. Steroid treatment is recommended 
as the first-line drug in all patients with generalized MG who 
do not respond to thymectomy [25]. Anticholinesterase drug 
monotherapy cannot induce remission of generalized MG 
and may mask ongoing autoimmune damage. Concurrent 
steroid treatment is therefore required in these cases [10]. 
Steroid therapy was used more frequently in generalized 
MG patients (82%) than in patients with ocular MG (57%), 
although the difference was not significant. In cases of 
myasthenic crisis, various treatments such as pulse steroid 
therapy, plasmapheresis, and intravenous immunoglobulin 
therapy can be considered [24]. High dose pulse steroid 
treatment was performed more frequently in the generalized 
MG group (35%) than it was in the ocular MG group (21%), 
although the difference was not statistically significant (p = 
0.525). A previous study reported that nearly all ocular MG 
patients (93%) illustrated some symptomatic improvement 
after anticholinesterase monotherapy [7], although ptosis 
has been shown to respond better to to this treatment than 
does diplopia [8]. In another recent study conducted in 
Thailand, ocular MG patients presenting with initial symp-
toms of ptosis and diplopia showed a decreased response to 
anticholinesterase treatment compared to another MG group 
presenting without initial symptoms of ptosis and diplopia 
[26]. Anticholinesterase drugs improve symptoms of MG in 
nearly all ocular and generalized MG patients, but the ther-
apeutic effects are limited. Thus, most patients require addi-
tional immunosuppressive treatment such as corticosteroid 
treatment [27]. Although still controversial, there are several Korean J Ophthalmol Vol.25, No.1, 2011
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studies which have insisted that systemic steroid treatment 
in ocular MG patients can prevent disease progression to 
generalized MG [6,8,9,11,12,28]. In this study, 57% of the 
ocular MG group received steroid treatment since anti-
cholinesterase drug monotherapy alone did not induce com-
plete remission.
Four of 71 patients presented with open angle glaucoma, 
and all of them were receiving long-term corticosteroid treat-
ment to induce remission (mean, 4.7 years). Corticosteroids 
increase the risk of glaucoma by increasing the intraocular 
pressure when administered exogenously (topically, periocu-
larly or systemically) and in certain conditions of increased 
endogenous production (e.g., Cushing’s syndrome) [29]. In 
addition, prolonged use of corticosteroids is a significant risk 
factor for the development of posterior subcapsular cataract 
[30]. Nine of 12 patients who presented with cataract had 
posterior subcapsular cataract, and three of 12 cataract pa-
tients required cataract surgery.
Interestingly, three patients developed symptomatic cen-
tral serous chorioretinopathy during steroid treatment for 
MG, one of the least known complications of steroid treatment. 
Although idiopathic central serous chorioretinopathy is 
known to be mild with spontaneous recovery and minimal 
long-term effects on visual acuity, irreversible visual impair-
ment may occur as a result of long-term steroid therapy [31]. 
Although one of the three central serous chorioretinopathy 
patients recovered without treatment, the other two patients 
showed serous detachment of the neurosensory retina, con-
firmed by optical coherence tomography at the final fol-
low-up visit, and the final visual acuities of the central serous 
chorioretinopathy-affected eyes were <20/100.
Systemic complications associated with steroid treatment 
include aseptic bone necrosis, hyperglycemia, osteoporosis, 
immune compromise, hypertension, growth retardation in 
children and proximal myopathy [32], with most complications 
correlating with the cumulative dose. Children and the elderly 
are particularly susceptible to corticosteroid complications. 
All three pediatric patients had short stature, and osteopo-
rosis was diagnosed in six of the eight elderly patients (>60 
years) during the follow-up period. An important method for 
preventing complications in patients receiving cortico-
steroids is to limit the total steroid dose. One way to reduce 
the steroid dose is by performing early thymectomy during 
the course of treatment. Thymectomy is accepted as an effec-
tive treatment for MG [33], for which it is considered a first 
line immune treatment [10]. Thymectomy was performed 
in 65% of generalized MG patients, and the majority was 
able to reduce steroid dosage while continuing symptom 
improvement.  
To date, MG has been predominantly researched by neu-
rologists, and as a result, ophthalmic complications other than 
ptosis and diplopia have not been thoroughly researched. 
Neurologists may not detect ocular symptoms and signs oth-
er than ptosis and diplopia or may not be aware of the oph-
thalmic complications that can result from combined auto-
immune diseases and steroid treatment. As a result, MG pa-
tients with ophthalmic signs and symptoms may not receive 
immediate proper ophthalmic management. We evaluated 
ophthalmic complications in addition to ptosis and diplopia 
in relation to the presence of autoimmune diseases and long 
term steroid treatment. It is important that patients with ocu-
lar MG or generalized MG with ophthalmic symptoms 
should undergo regular eye examinations. In cases of MG, 
the neurologist should recommend an eye specialist who is 
well aware of the ophthalmic complications of the disease 
and its prognosis. Most importantly, careful attention must be 
given to generalized MG patients because they have a higher 
risk of ophthalmic and other problems associated with sys-
temic autoimmune disease and long-term treatment of MG 
than do ocular MG patients. 
Selection bias, which is commonly found in retrospective 
studies, was a potential problem in the current study as our 
analysis was limited to information available from medical 
records. It was impossible to quantitatively compare the 
treatment efficacies of anticholinesterase inhibitors and ste-
roids or to objectively evaluate the severity of ptosis and dip-
lopia due to fluctuations in disease status and treatment 
response. 
In conclusion, MG patients may experience less common 
eye problems including dry eye symptoms, pain, blurry vi-
sion, and tearing in addition to more well-known symptoms 
such as ptosis and diplopia. These less common eye prob-
lems can impair quality of life and should not be neglected. 
In addition, common autoimmune diseases such as thyroid 
associated ophthalmopathy, Sjogren’s disease, multiple scle-
rosis and Behcet’s disease may develop in MG patients, fur-
ther supporting ophthalmic complications. In generalized 
MG, the incidence of autoimmune disease is higher and more 
variable than that in ocular MG patients; therefore, general-
ized MG patients should be screened for ophthalmic compli-
cations on a regular basis. In MG patients with long-term ste-
roid use, glaucoma may develop due to optic nerve damage 
and can lead to irreversible visual field defects. Since loss of 
vision is often only recognized when the disease is advanced, 
early detection of glaucoma is very important in a back-
ground of MG. Long term steroid treatment in MG patients 
may also cause complications of posterior polar cataract and 
central serous chorioretinopathy, effects which must be taken 
into careful consideration.
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